Abstract
Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 52-56 |
| Number of pages | 5 |
| Journal | Current Opinion in Immunology |
| Volume | 47 |
| DOIs | |
| State | Published - Aug 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
CD8+ T cell programming by cytomegalovirus vectors : applications in prophylactic and therapeutic vaccination. / Frueh, Klaus; Picker, Louis.
In: Current Opinion in Immunology, Vol. 47, 01.08.2017, p. 52-56.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - CD8+ T cell programming by cytomegalovirus vectors
T2 - applications in prophylactic and therapeutic vaccination
AU - Frueh, Klaus
AU - Picker, Louis
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
AB - Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.
UR - http://www.scopus.com/inward/record.url?scp=85024867112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024867112&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2017.06.010
DO - 10.1016/j.coi.2017.06.010
M3 - Review article
C2 - 28734175
AN - SCOPUS:85024867112
VL - 47
SP - 52
EP - 56
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
SN - 0952-7915
ER -